Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Revelation Biosciences (NASDAQ: REVB) has received formal notification from Nasdaq confirming its continued listing status, having met all compliance requirements. The company recently initiated its PRIME Phase 1b clinical study investigating intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
The U.S. multi-site placebo-controlled study will evaluate escalating doses across five cohorts, enrolling up to 40 patients. CEO James Rolke emphasized that maintaining Nasdaq listing helps preserve stockholder liquidity, provides capital access, and aids in talent retention. The company plans to share study results with shareholders at each milestone throughout 2025.
Revelation Biosciences (NASDAQ: REVB) ha ricevuto una notifica formale da Nasdaq che conferma il suo stato di quotazione, avendo soddisfatto tutti i requisiti di conformità. L'azienda ha recentemente avviato il suo studio clinico PRIME Fase 1b che indaga sull'amministrazione endovenosa di Gemini in pazienti con malattia renale cronica (CKD) di stadio 3 e 4.
Lo studio controllato con placebo, multi-sito negli Stati Uniti, valuterà dosi crescenti su cinque coorti, arruolando fino a 40 pazienti. Il CEO James Rolke ha sottolineato che mantenere la quotazione su Nasdaq aiuta a preservare la liquidità degli azionisti, fornisce accesso al capitale e facilita la retention dei talenti. L'azienda prevede di condividere i risultati dello studio con gli azionisti ad ogni traguardo nel corso del 2025.
Revelation Biosciences (NASDAQ: REVB) ha recibido una notificación formal de Nasdaq confirmando su estado de cotización, habiendo cumplido con todos los requisitos de cumplimiento. La compañía ha iniciado recientemente su estudio clínico PRIME Fase 1b que investiga la administración intravenosa de Gemini en pacientes con Enfermedad Renal Crónica (ERC) en etapas 3 y 4.
El estudio controlado con placebo y multi-sitio en EE. UU. evaluará dosis crecientes en cinco cohortes, inscribiendo hasta 40 pacientes. El CEO James Rolke enfatizó que mantener la cotización en Nasdaq ayuda a preservar la liquidez de los accionistas, proporciona acceso a capital y ayuda en la retención de talento. La compañía planea compartir los resultados del estudio con los accionistas en cada hito a lo largo de 2025.
Revelation Biosciences (NASDAQ: REVB)는 모든 준수 요건을 충족하여 Nasdaq으로부터 계속 상장 상태에 대한 공식 통지를 받았습니다. 최근 회사는 3기 및 4기 만성 신장 질환(CKD) 환자에게 정맥 주사로 Gemini를 투여하는 PRIME 1b 임상 연구를 시작했습니다.
미국의 다기관 위약 대조 연구는 다섯 개의 집단에서 용량을 증가시키며 최대 40명의 환자를 등록할 예정입니다. CEO 제임스 롤케는 Nasdaq 상장을 유지하는 것이 주주의 유동성을 보존하고 자본 접근을 제공하며 인재 유지를 돕는다고 강조했습니다. 회사는 2025년 동안 각 이정표에 따라 주주와 연구 결과를 공유할 계획입니다.
Revelation Biosciences (NASDAQ: REVB) a reçu une notification formelle de Nasdaq confirmant son statut de cotation, ayant satisfait à toutes les exigences de conformité. L'entreprise a récemment lancé son étude clinique PRIME Phase 1b qui examine l'administration intraveineuse de Gemini chez des patients atteints de maladie rénale chronique (MRC) au stade 3 et 4.
L'étude contrôlée par placebo, multi-sites aux États-Unis, évaluera des doses croissantes dans cinq cohortes, recrutant jusqu'à 40 patients. Le PDG James Rolke a souligné que le maintien de la cotation sur Nasdaq aide à préserver la liquidité des actionnaires, offre un accès au capital et aide à la rétention des talents. L'entreprise prévoit de partager les résultats de l'étude avec les actionnaires à chaque étape tout au long de 2025.
Revelation Biosciences (NASDAQ: REVB) hat eine formelle Mitteilung von Nasdaq erhalten, die den Status der weiteren Listung bestätigt, nachdem alle Compliance-Anforderungen erfüllt wurden. Das Unternehmen hat kürzlich seine PRIME Phase 1b klinische Studie gestartet, die die intravenöse Verabreichung von Gemini bei Patienten mit chronischer Nierenerkrankung (CKD) im Stadium 3 und 4 untersucht.
Die multizentrische, placebo-kontrollierte Studie in den USA wird steigende Dosen in fünf Kohorten bewerten und bis zu 40 Patienten einschreiben. CEO James Rolke betonte, dass die Aufrechterhaltung der Nasdaq-Listung dazu beiträgt, die Liquidität der Aktionäre zu erhalten, den Zugang zu Kapital zu ermöglichen und die Talentbindung zu unterstützen. Das Unternehmen plant, die Studienergebnisse im Laufe des Jahres 2025 mit den Aktionären bei jedem Meilenstein zu teilen.
- Maintained Nasdaq listing status, ensuring continued market access and liquidity
- Launched Phase 1b clinical trial for Gemini in CKD patients
- None.
Insights
The dual announcement of NASDAQ listing compliance and Phase 1b trial initiation represents a strategic inflection point for Revelation Biosciences. The PRIME study targeting Stage 3 and 4 CKD patients is particularly noteworthy, as this represents a significant market opportunity - CKD affects approximately 37 million adults in the US alone, with Stage 3 and 4 patients representing a substantial subset requiring innovative therapeutic interventions.
The study design with five escalating dose cohorts demonstrates a methodical approach to safety and efficacy evaluation. This careful progression is important for immunomodulatory therapies, where finding the optimal therapeutic window is essential for success. The multi-site approach enhances patient recruitment potential and data reliability.
Maintaining NASDAQ listing compliance is particularly significant as it ensures continued access to capital markets and institutional investors. This is important for clinical-stage biotech companies that typically require substantial funding to advance their pipeline. The compliance status also provides a foundation for potential future financing rounds or strategic partnerships, which are often necessary for late-phase clinical development.
The focus on rebalancing inflammation in CKD represents a novel approach in a field traditionally dominated by symptom management and dialysis. Success in this Phase 1b study could position Revelation as an innovator in the nephrology space, where new therapeutic approaches are urgently needed. The company's commitment to regular milestone updates suggests a transparent approach to shareholder communication, which is essential for maintaining investor confidence during the clinical development process.
On January 21, 2025, Revelation announced the commencement of its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The
“We believe being listed on Nasdaq helps us maintain liquidity for our stockholders, gives us access to capital, and allows us to attract and retain the people we need to accomplish our research and drive our company forward in 2025 and beyond,” said James Rolke, Chief Executive Officer, Revelation. “Our goal is to accelerate our growth and work to build a robust, high value company. We have recently commenced the Phase 1b PRIME (Preconditioning Immunostimulatory Evaluation) clinical study of escalating doses in the
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224415789/en/
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences, Inc.
FAQ
What is the size and scope of REVB's PRIME Phase 1b clinical study?
When did Revelation Biosciences (REVB) announce its PRIME clinical study?
What is the significance of REVB maintaining its Nasdaq listing?
What type of patients are eligible for REVB's PRIME clinical study?
